Search results for "Highlights"


 
Results 61 - 70 of about 254 for "Highlights".

Tool may help stratify risk for hypoglycemia-related ED and hospital use

The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
September 2017

Cardiovascular disease and mortality appear lower in patients on SGLT2 inhibitors

The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
August 2017

Metformin appears to prevent type 2 diabetes, study indicates

Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
August 2017

Dapagliflozin appears effective as adjunct therapy in patients with type 1 diabetes

Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
October 2017

Minority of patients with type 1 diabetes achieve ADA goals for glycemic control, study finds

Despite increasing adoption of insulin pumps and continuous glucose monitors, control of HbA1c hasn't necessarily improved, the authors noted.
February 2019

Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds

The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
July 2017

Oral glucose tolerance test results may be influenced by height, study finds

Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.
June 2017

SGLT2 inhibitors may have class effect for reduction of cardiac risk

The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
June 2017

Treatment deintensification uncommon in type 2 diabetes

status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
May 2017

Approved drugs for diabetic neuropathy better than placebo, review finds

In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
April 2017

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next